AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. TWST
  4. [Form 4] Twist Bioscience Corporation Insider Trading Activity

[Form 4] Twist Bioscience Corporation Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Emily M. Leproust, Chief Executive Officer and Director of Twist Bioscience, reported insider trading activity on June 20, 2025. The transaction involved a mandatory "sell to cover" of 1,678 shares of Common Stock at $35.755 per share to satisfy tax withholding obligations related to vesting Restricted Stock Units.

Following the transaction, Leproust maintains direct ownership of 645,782 shares of Common Stock. Additionally, she holds several employee stock options:

  • 150,879 options at $8.82 (expires 09/28/2027)
  • 266,539 options at $26.66 (expires 11/18/2028)
  • 131,290 options at $23.33 (expires 10/23/2029)
  • 64,950 performance-based options at $67.85 (expires 08/31/2030)

The reported sale was not discretionary but rather mandated by the company's equity incentive plan requirements for tax withholding purposes.

Emily M. Leproust, Amministratore Delegato e Direttrice di Twist Bioscience, ha segnalato un'attivit脿 di insider trading il 20 giugno 2025. L'operazione ha riguardato una vendita obbligatoria "sell to cover" di 1.678 azioni ordinarie al prezzo di 35,755 dollari per azione, al fine di soddisfare gli obblighi fiscali legati al vesting di Restricted Stock Units.

In seguito alla transazione, Leproust detiene direttamente 645.782 azioni ordinarie. Inoltre, possiede diverse opzioni azionarie per dipendenti:

  • 150.879 opzioni a 8,82 $ (scadenza 28/09/2027)
  • 266.539 opzioni a 26,66 $ (scadenza 18/11/2028)
  • 131.290 opzioni a 23,33 $ (scadenza 23/10/2029)
  • 64.950 opzioni basate sulle performance a 67,85 $ (scadenza 31/08/2030)

La vendita riportata non 猫 stata discrezionale, ma obbligatoria in base ai requisiti del piano di incentivazione azionaria dell'azienda per finalit脿 di ritenuta fiscale.

Emily M. Leproust, Directora Ejecutiva y Directora de Twist Bioscience, report贸 una actividad de operaciones internas el 20 de junio de 2025. La transacci贸n consisti贸 en una venta obligatoria "sell to cover" de 1,678 acciones ordinarias a 35.755 d贸lares por acci贸n para cumplir con las obligaciones fiscales relacionadas con la consolidaci贸n de Unidades de Acciones Restringidas.

Tras la operaci贸n, Leproust mantiene la propiedad directa de 645,782 acciones ordinarias. Adem谩s, posee varias opciones sobre acciones para empleados:

  • 150,879 opciones a 8.82 $ (vence el 28/09/2027)
  • 266,539 opciones a 26.66 $ (vence el 18/11/2028)
  • 131,290 opciones a 23.33 $ (vence el 23/10/2029)
  • 64,950 opciones basadas en desempe帽o a 67.85 $ (vence el 31/08/2030)

La venta reportada no fue discrecional, sino que estuvo mandatada por los requisitos del plan de incentivos accionarios de la empresa para la retenci贸n fiscal.

Emily M. Leproust, Twist Bioscience鞚� 斓滉碃瓴届榿鞛� 瓴� 鞚挫偓電� 2025雲� 6鞗� 20鞚� 雮措秬鞛� 瓯半灅 頇滊彊鞚� 氤搓碃頄堨姷雼堧嫟. 鞚措矆 瓯半灅電� 鞝滍暅 欤检嫕 雼渼(RSU)鞚� 甓岆Μ 頇曥爼鞐� 霐半ジ 靹戈笀 鞗愳矞歆曥垬 鞚橂毳� 於╈”頃橁赴 鞙勴暣 1,678欤检潣 氤错喌欤茧ゼ 欤茧嫻 35.755雼煬鞐� 鞚橂鞝侅溂搿� "sell to cover" 毵る弰頃� 瓴冹瀰雼堧嫟.

瓯半灅 頉� Leproust電� 歆侅爲鞝侅溂搿� 645,782欤�鞚� 氤错喌欤茧ゼ 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 霕愴暅 鞐煬 歆侅洂 欤检嫕 毵れ垬靹犿儩甓岇潉 氤挫湢頃橁碃 鞛堨姷雼堧嫟:

  • 150,879欤� 鞓奠厴, 頄夓偓 臧�瓴� $8.82 (毵岆鞚� 2027雲� 9鞗� 28鞚�)
  • 266,539欤� 鞓奠厴, 頄夓偓 臧�瓴� $26.66 (毵岆鞚� 2028雲� 11鞗� 18鞚�)
  • 131,290欤� 鞓奠厴, 頄夓偓 臧�瓴� $23.33 (毵岆鞚� 2029雲� 10鞗� 23鞚�)
  • 64,950欤� 靹标臣 旮半皹 鞓奠厴, 頄夓偓 臧�瓴� $67.85 (毵岆鞚� 2030雲� 8鞗� 31鞚�)

氤搓碃霅� 毵る弰電� 鞛勳潣搿� 鞚措（鞏挫 瓴冹澊 鞎勲媹氅�, 須岇偓鞚� 欤检嫕 鞚胳劶韹半笇 瓿勴殟鞐� 霐半ジ 靹戈笀 鞗愳矞歆曥垬 鞚橂鞐� 鞚橅暣 臧曥牅霅� 瓴冹瀰雼堧嫟.

Emily M. Leproust, Directrice G茅n茅rale et Administratrice de Twist Bioscience, a d茅clar茅 une op茅ration d'initi茅 le 20 juin 2025. La transaction concernait une vente obligatoire "sell to cover" de 1 678 actions ordinaires au prix de 35,755 $ par action afin de satisfaire aux obligations fiscales li茅es 脿 l'acquisition de Restricted Stock Units.

Apr猫s cette op茅ration, Leproust d茅tient directement 645 782 actions ordinaires. Elle d茅tient 茅galement plusieurs options d'achat d'actions pour employ茅s :

  • 150 879 options 脿 8,82 $ (expiration le 28/09/2027)
  • 266 539 options 脿 26,66 $ (expiration le 18/11/2028)
  • 131 290 options 脿 23,33 $ (expiration le 23/10/2029)
  • 64 950 options bas茅es sur la performance 脿 67,85 $ (expiration le 31/08/2030)

La vente d茅clar茅e n'茅tait pas discr茅tionnaire, mais impos茅e par les exigences du plan d'incitation en actions de la soci茅t茅 pour les besoins de retenue fiscale.

Emily M. Leproust, Gesch盲ftsf眉hrerin und Direktorin von Twist Bioscience, meldete am 20. Juni 2025 Insiderhandelst盲tigkeiten. Die Transaktion beinhaltete einen verpflichtenden "sell to cover"-Verkauf von 1.678 Stammaktien zu einem Preis von 35,755 USD pro Aktie, um steuerliche Verpflichtungen im Zusammenhang mit der 脺bertragung von Restricted Stock Units zu erf眉llen.

Nach der Transaktion h盲lt Leproust direkt 645.782 Stammaktien. Zus盲tzlich besitzt sie mehrere Mitarbeiteraktienoptionen:

  • 150.879 Optionen zu 8,82 $ (Ablauf 28.09.2027)
  • 266.539 Optionen zu 26,66 $ (Ablauf 18.11.2028)
  • 131.290 Optionen zu 23,33 $ (Ablauf 23.10.2029)
  • 64.950 leistungsabh盲ngige Optionen zu 67,85 $ (Ablauf 31.08.2030)

Der gemeldete Verkauf war nicht freiwillig, sondern durch die Anforderungen des Aktienanreizplans des Unternehmens zur Steuerabf眉hrung vorgeschrieben.

Positive
  • None.
Negative
  • None.

Emily M. Leproust, Amministratore Delegato e Direttrice di Twist Bioscience, ha segnalato un'attivit脿 di insider trading il 20 giugno 2025. L'operazione ha riguardato una vendita obbligatoria "sell to cover" di 1.678 azioni ordinarie al prezzo di 35,755 dollari per azione, al fine di soddisfare gli obblighi fiscali legati al vesting di Restricted Stock Units.

In seguito alla transazione, Leproust detiene direttamente 645.782 azioni ordinarie. Inoltre, possiede diverse opzioni azionarie per dipendenti:

  • 150.879 opzioni a 8,82 $ (scadenza 28/09/2027)
  • 266.539 opzioni a 26,66 $ (scadenza 18/11/2028)
  • 131.290 opzioni a 23,33 $ (scadenza 23/10/2029)
  • 64.950 opzioni basate sulle performance a 67,85 $ (scadenza 31/08/2030)

La vendita riportata non 猫 stata discrezionale, ma obbligatoria in base ai requisiti del piano di incentivazione azionaria dell'azienda per finalit脿 di ritenuta fiscale.

Emily M. Leproust, Directora Ejecutiva y Directora de Twist Bioscience, report贸 una actividad de operaciones internas el 20 de junio de 2025. La transacci贸n consisti贸 en una venta obligatoria "sell to cover" de 1,678 acciones ordinarias a 35.755 d贸lares por acci贸n para cumplir con las obligaciones fiscales relacionadas con la consolidaci贸n de Unidades de Acciones Restringidas.

Tras la operaci贸n, Leproust mantiene la propiedad directa de 645,782 acciones ordinarias. Adem谩s, posee varias opciones sobre acciones para empleados:

  • 150,879 opciones a 8.82 $ (vence el 28/09/2027)
  • 266,539 opciones a 26.66 $ (vence el 18/11/2028)
  • 131,290 opciones a 23.33 $ (vence el 23/10/2029)
  • 64,950 opciones basadas en desempe帽o a 67.85 $ (vence el 31/08/2030)

La venta reportada no fue discrecional, sino que estuvo mandatada por los requisitos del plan de incentivos accionarios de la empresa para la retenci贸n fiscal.

Emily M. Leproust, Twist Bioscience鞚� 斓滉碃瓴届榿鞛� 瓴� 鞚挫偓電� 2025雲� 6鞗� 20鞚� 雮措秬鞛� 瓯半灅 頇滊彊鞚� 氤搓碃頄堨姷雼堧嫟. 鞚措矆 瓯半灅電� 鞝滍暅 欤检嫕 雼渼(RSU)鞚� 甓岆Μ 頇曥爼鞐� 霐半ジ 靹戈笀 鞗愳矞歆曥垬 鞚橂毳� 於╈”頃橁赴 鞙勴暣 1,678欤检潣 氤错喌欤茧ゼ 欤茧嫻 35.755雼煬鞐� 鞚橂鞝侅溂搿� "sell to cover" 毵る弰頃� 瓴冹瀰雼堧嫟.

瓯半灅 頉� Leproust電� 歆侅爲鞝侅溂搿� 645,782欤�鞚� 氤错喌欤茧ゼ 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 霕愴暅 鞐煬 歆侅洂 欤检嫕 毵れ垬靹犿儩甓岇潉 氤挫湢頃橁碃 鞛堨姷雼堧嫟:

  • 150,879欤� 鞓奠厴, 頄夓偓 臧�瓴� $8.82 (毵岆鞚� 2027雲� 9鞗� 28鞚�)
  • 266,539欤� 鞓奠厴, 頄夓偓 臧�瓴� $26.66 (毵岆鞚� 2028雲� 11鞗� 18鞚�)
  • 131,290欤� 鞓奠厴, 頄夓偓 臧�瓴� $23.33 (毵岆鞚� 2029雲� 10鞗� 23鞚�)
  • 64,950欤� 靹标臣 旮半皹 鞓奠厴, 頄夓偓 臧�瓴� $67.85 (毵岆鞚� 2030雲� 8鞗� 31鞚�)

氤搓碃霅� 毵る弰電� 鞛勳潣搿� 鞚措（鞏挫 瓴冹澊 鞎勲媹氅�, 須岇偓鞚� 欤检嫕 鞚胳劶韹半笇 瓿勴殟鞐� 霐半ジ 靹戈笀 鞗愳矞歆曥垬 鞚橂鞐� 鞚橅暣 臧曥牅霅� 瓴冹瀰雼堧嫟.

Emily M. Leproust, Directrice G茅n茅rale et Administratrice de Twist Bioscience, a d茅clar茅 une op茅ration d'initi茅 le 20 juin 2025. La transaction concernait une vente obligatoire "sell to cover" de 1 678 actions ordinaires au prix de 35,755 $ par action afin de satisfaire aux obligations fiscales li茅es 脿 l'acquisition de Restricted Stock Units.

Apr猫s cette op茅ration, Leproust d茅tient directement 645 782 actions ordinaires. Elle d茅tient 茅galement plusieurs options d'achat d'actions pour employ茅s :

  • 150 879 options 脿 8,82 $ (expiration le 28/09/2027)
  • 266 539 options 脿 26,66 $ (expiration le 18/11/2028)
  • 131 290 options 脿 23,33 $ (expiration le 23/10/2029)
  • 64 950 options bas茅es sur la performance 脿 67,85 $ (expiration le 31/08/2030)

La vente d茅clar茅e n'茅tait pas discr茅tionnaire, mais impos茅e par les exigences du plan d'incitation en actions de la soci茅t茅 pour les besoins de retenue fiscale.

Emily M. Leproust, Gesch盲ftsf眉hrerin und Direktorin von Twist Bioscience, meldete am 20. Juni 2025 Insiderhandelst盲tigkeiten. Die Transaktion beinhaltete einen verpflichtenden "sell to cover"-Verkauf von 1.678 Stammaktien zu einem Preis von 35,755 USD pro Aktie, um steuerliche Verpflichtungen im Zusammenhang mit der 脺bertragung von Restricted Stock Units zu erf眉llen.

Nach der Transaktion h盲lt Leproust direkt 645.782 Stammaktien. Zus盲tzlich besitzt sie mehrere Mitarbeiteraktienoptionen:

  • 150.879 Optionen zu 8,82 $ (Ablauf 28.09.2027)
  • 266.539 Optionen zu 26,66 $ (Ablauf 18.11.2028)
  • 131.290 Optionen zu 23,33 $ (Ablauf 23.10.2029)
  • 64.950 leistungsabh盲ngige Optionen zu 67,85 $ (Ablauf 31.08.2030)

Der gemeldete Verkauf war nicht freiwillig, sondern durch die Anforderungen des Aktienanreizplans des Unternehmens zur Steuerabf眉hrung vorgeschrieben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Leproust Emily M.
(Last) (First) (Middle)
C/O TWIST BIOSCIENCE CORPORATION
681 GATEWAY BLVD.
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/20/2025 S 1,678(1) D $35.755 645,782 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy) $5.95 (2) 09/28/2025 Common Stock 0 0 D
Employee Stock Option (right to buy) $8.82 (3) 09/28/2027 Common Stock 0 150,879 D
Employee Stock Option (right to buy) $26.66 (4) 11/18/2028 Common Stock 0 266,539 D
Employee Stock Option (right to buy) $23.33 (5) 10/23/2029 Common Stock 0 131,290 D
Employee Stock Option (right to buy) $67.85 12/19/2022 08/31/2030 Common Stock 64,950 64,950(6) D
Explanation of Responses:
1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
2. The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
3. The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
4. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
5. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
6. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
Remarks:
/s/ Kendra Fox, as Attorney-in-Fact for Emily M. Leproust 06/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many TWST shares did CEO Emily Leproust sell on June 20, 2025?

CEO Emily Leproust sold 1,678 shares of TWST common stock on June 20, 2025 at a price of $35.755 per share. This sale was specifically to cover tax withholding obligations related to the vesting of Restricted Stock Units and was not a discretionary trade.

How many shares of TWST does Emily Leproust own after the June 2025 transaction?

Following the reported transaction, Emily Leproust directly owns 645,782 shares of TWST common stock. Additionally, she holds several stock options, including 150,879 options at $8.82, 266,539 options at $26.66, 131,290 options at $23.33, and 64,950 options at $67.85.

What is the exercise price of TWST CEO's most recent stock options?

The most recent stock options granted to Emily Leproust (as shown in the filing) have an exercise price of $67.85. These are performance stock options that were granted on September 1, 2020, and vested on December 19, 2022 after meeting specific performance criteria.

Was TWST CEO's June 2025 stock sale discretionary?

No, the stock sale was not discretionary. According to the filing, the sale was mandated by the company's equity incentive plans to cover tax withholding obligations through a 'sell to cover' transaction related to the vesting of Restricted Stock Units.
Stock TWST logo
Twist Bioscience

NASDAQ:TWST

TWST Rankings

#2821 Ranked by Market Cap
N/A Ranked by Dividends

TWST Latest News

Aug 4, 2025
Twist Bioscience Announces Fiscal 2025 Third Quarter Financial Results
Jul 31, 2025
Twist Bioscience Expands In Vivo Antibody Discovery Services with Launch of Humanized Transgenic Mouse Model
Jul 24, 2025
Twist Bioscience Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jul 14, 2025
Twist Bioscience to Report Fiscal 2025 Third Quarter Financial Results on Monday, August 4, 2025
Jul 7, 2025
Twist Bioscience Expands Express Delivery Turnaround Time to All Gene Fragments Regardless of Format

TWST Latest SEC Filings

Aug 4, 2025
[10-Q] Twist Bioscience Corporation Quarterly Earnings Report
Aug 4, 2025
[144] Twist Bioscience Corporation SEC Filing
Aug 4, 2025
[144] Twist Bioscience Corporation SEC Filing
Aug 4, 2025
[144] Twist Bioscience Corporation SEC Filing
Aug 4, 2025
[144] Twist Bioscience Corporation SEC Filing

TWST Stock Data

2.02B
58.74M
1.97%
115.74%
17.93%
Diagnostics & Research
Biological Products, (no Disgnostic Substances)
United States
SOUTH SAN FRANCISCO